Concepedia

A Phase I Trial of a 3-Day Topotecan Q 21 Days for Recurrent Epithelial Cancers of the Ovary, Fallopian Tube, and Peritoneum

John V. Brown, William A. Peters, Mark A. Rettenmaier, Beth Y. Karlan, Robert A. Dillman, Michael Smith, Charles W. Drescher, John P. Micha

Gynecologic Oncology · 2000 · 22 citations · 19 references

DOI

Concepts

References

19

Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer.

W ten Bokkel Huinink, Martin Gore, J Carmichael et al. · Journal of Clinical Oncology · 1997 · 683 citations

, , +17

Creatinine Clearance: Bedside Estimate

Roger W. Jelliffe · Annals of Internal Medicine · 1973 · 494 citations

, , +17

Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: results of a large European phase II study.

G.J. Creemers, Giorgio Bolis, M. Gore et al. · Journal of Clinical Oncology · 1996 · 386 citations

, , +17

Phase I and pharmacologic study of topotecan: a novel topoisomerase I inhibitor.

Eric K. Rowinsky, L B Grochow, Carolyn B. Hendricks et al. · Journal of Clinical Oncology · 1992 · 358 citations

, , +15

Topotecan for the treatment of advanced epithelial ovarian cancer: an open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel.

M. A. Bookman, Henric Malmström, Giorgio Bolis et al. · Journal of Clinical Oncology · 1998 · 334 citations

, , +16